Prognostic value of telomerase and DNA ploidy in laryngeal carcinoma.
Prognosis of carcinoma of the larynx is currently based on the morphologic analysis of the tumor extent, differentiation grading and type of microscopic invasion. The DNA ploidy status and the cell proliferation activity may give complementary information about the prognosis. Telomerase may be used as a measure of tumor proliferation. The aim of this work was to investigate the probable application of telomerase as a measure of cell immortalization as well as DNA ploidy as a measure of cell proliferation in the prognosis of patients with laryngeal carcinoma. The work was carried out as a prospective observational study that included 35 patients with laryngeal carcinoma who were treated surgically at Ain Shams University Hospitals, Cairo, Egypt. Flowcytometric analysis and biochemical assay of telomerase using human Telomerase Reverse Transcriptase (hTERT) mRNA assay by RT-PCR in resected specimens were done. The proliferative indices in different parts of the tumor were found to be significantly different from each other, with those of tumor edges being the highest. The ploidy status at the edge of the tumor was significantly different between surviving and non-surviving patients, while the tumor core proliferative index was found to be significantly lower in patients without recurrence than those with recurrence. A gradient of telomerase levels was noticed, with levels from tumor cores being the highest followed by tumor edges, resection margins and the lowest levels in lymph nodes. Multivariate analysis showed hTERT levels in tumor edges to significantly affect survival. Both Flowcytometric parameters and telomerase activity may be useful as a prognostic factor for survival in patients with laryngeal carcinoma. Telomerase activity may be used for biologic demarcation for conservational laryngeal surgery, as well as a 'spectral' marker.
El Samny
Talaat
T
Department of Otolaryngology, Ain Shams University Faculty of Medicine, Cairo, Egypt.
El Halaby
Hisham
H
El Fiky
Lobna
L
Nassar
Mohamed
M
El Makhzangy
Ali
A
Eissa
Sannaa
S
D000328:Adult; D000368:Aged; D049109:Cell Proliferation; D004273:DNA, Neoplasm / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007822:Laryngeal Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D011003:Ploidies; D011379:Prognosis; D011446:Prospective Studies; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019098:Telomerase / Q000032:analysis* / Q000235:genetics
D004273:DNA, Neoplasm; D012333:RNA, Messenger; D019098:Telomerase
Laryngoscope. 1993 May;103(5):538-40
8483372
Cell. 1997 Aug 22;90(4):785-95
9288757
Curr Biol. 1998 Jan 29;8(3):177-80
9443919
Nature. 1984 Jul 12-18;310(5973):154-7
6330571
Arch Otolaryngol Head Neck Surg. 1998 Jul;124(7):784-8
9677114
Laryngoscope. 1993 May;103(5):498-502
8483365
Mol Med Today. 1999 Mar;5(3):114-22
10203735
Laryngoscope. 1982 Sep;92(9 Pt 1):1064-9
7121161
Laryngoscope. 2000 Mar;110(3 Pt 1):391-6
10718425
Arch Otolaryngol Head Neck Surg. 1992 Feb;118(2):169-73
1540348
Acta Otolaryngol. 1992;112(2):376-82
1605011
Anticancer Res. 2001 Nov-Dec;21(6A):4011-5
11911285
Mol Cell Biol. 1996 Jun;16(6):2932-9
8649404
Science. 1994 Dec 23;266(5193):2011-5
7605428
Am J Surg. 1986 Oct;152(4):396-402
3766870
Clin Cancer Res. 1996 Nov;2(11):1895-900
9816146
Cancer. 1991 Jan 1;67(1):141-9
1985711
Ann Otol Rhinol Laryngol. 1995 Jul;104(7):503-10
7598360
Cancer. 1998 Jun 1;82(11):2159-65
9610695